Astria Therapeutics Inc

Astria Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein in Phase 1b/2 clinical trials for hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist in clinical development for atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. Formerly known as Catabasis Pharmaceuticals, Inc., it changed its name to Astria Therapeutics, Inc. in September 2021, was incorporated in 2008, and is headquartered in Boston, Massachusetts. As of January 23, 2026, it operates as a subsidiary of BioCryst Pharmaceuticals, Inc.